131 related articles for article (PubMed ID: 11727285)
1. Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology.
Cazenave JP; Davis K; Corash L
Semin Hematol; 2001 Oct; 38(4 Suppl 11):46-54. PubMed ID: 11727285
[TBL] [Abstract][Full Text] [Related]
2. Amotosalen: Allogeneic Cellular Immunotherapies system, INTERCEPT Plasma System, INTERCEPT Platelet System, S 59.
BioDrugs; 2003; 17(1):66-8. PubMed ID: 12534321
[TBL] [Abstract][Full Text] [Related]
3. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
4. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial.
van Rhenen D; Gulliksson H; Cazenave JP; Pamphilon D; Ljungman P; Klüter H; Vermeij H; Kappers-Klunne M; de Greef G; Laforet M; Lioure B; Davis K; Marblie S; Mayaudon V; Flament J; Conlan M; Lin L; Metzel P; Buchholz D; Corash L;
Blood; 2003 Mar; 101(6):2426-33. PubMed ID: 12456508
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology.
Lin L
Semin Hematol; 2001 Oct; 38(4 Suppl 11):27-33. PubMed ID: 11727283
[TBL] [Abstract][Full Text] [Related]
6. [Feasibility study for Intercept platelets].
Bardiaux L; Vauzou S; Olivier B; Mathieu-Daude D; Durand E; Dite C; Roubinet F
Transfus Clin Biol; 2016 Nov; 23(4):212-216. PubMed ID: 27644172
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial.
McCullough J; Vesole DH; Benjamin RJ; Slichter SJ; Pineda A; Snyder E; Stadtmauer EA; Lopez-Plaza I; Coutre S; Strauss RG; Goodnough LT; Fridey JL; Raife T; Cable R; Murphy S; Howard F; Davis K; Lin JS; Metzel P; Corash L; Koutsoukos A; Lin L; Buchholz DH; Conlan MG
Blood; 2004 Sep; 104(5):1534-41. PubMed ID: 15138160
[TBL] [Abstract][Full Text] [Related]
8. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates.
Kaiser-Guignard J; Canellini G; Lion N; Abonnenc M; Osselaer JC; Tissot JD
Blood Rev; 2014 Nov; 28(6):235-41. PubMed ID: 25192602
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution.
van Rhenen DJ; Gulliksson H; Cazenave JP; Pamphilon D; Davis K; Flament J; Corash L
Transfus Med; 2004 Aug; 14(4):289-95. PubMed ID: 15285725
[TBL] [Abstract][Full Text] [Related]
10. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
[TBL] [Abstract][Full Text] [Related]
11. Determination
Thuku NW; Shikuku K; Mbugua A
Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
[TBL] [Abstract][Full Text] [Related]
12. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia.
Slichter SJ; Raife TJ; Davis K; Rheinschmidt M; Buchholz DH; Corash L; Conlan MG
Transfusion; 2006 May; 46(5):731-40. PubMed ID: 16686840
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of transfusions of autologous cryopreserved platelets derived from recombinant human thrombopoietin to support chemotherapy-associated severe thrombocytopenia: a randomised cross-over study.
Vadhan-Raj S; Kavanagh JJ; Freedman RS; Folloder J; Currie LM; Bueso-Ramos C; Verschraegen CF; Narvios AB; Connor J; Hoots WK; Broemeling LD; Lichtiger B
Lancet; 2002 Jun; 359(9324):2145-52. PubMed ID: 12090979
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation.
Estcourt L; Stanworth S; Doree C; Hopewell S; Murphy MF; Tinmouth A; Heddle N
Cochrane Database Syst Rev; 2012 May; (5):CD004269. PubMed ID: 22592695
[TBL] [Abstract][Full Text] [Related]
15. The impact of platelet transfusion characteristics on posttransfusion platelet increments and clinical bleeding in patients with hypoproliferative thrombocytopenia.
Triulzi DJ; Assmann SF; Strauss RG; Ness PM; Hess JR; Kaufman RM; Granger S; Slichter SJ
Blood; 2012 Jun; 119(23):5553-62. PubMed ID: 22496156
[TBL] [Abstract][Full Text] [Related]
16. [Clinical efficiency of transfusion of pathogen-inactivated platelet concentrates].
Nakastoev IM; Grachev AE; Gemdzhian ÉG; Tsyba NN; Zhuravlev VV; Krechetova AV; Kastrikina IS; Vatagina EA; Ryzhko VV; Gorodetskiĭ VM
Ter Arkh; 2013; 85(8):77-80. PubMed ID: 24137968
[TBL] [Abstract][Full Text] [Related]
17. Corrected count increment and percent platelet recovery as measures of posttransfusion platelet response: problems and a solution.
Davis KB; Slichter SJ; Corash L
Transfusion; 1999 Jun; 39(6):586-92. PubMed ID: 10378838
[TBL] [Abstract][Full Text] [Related]
18. Patient and product factors affecting platelet transfusion results.
Heim D; Passweg J; Gregor M; Buser A; Theocharides A; Arber C; Meyer-Monard S; Halter J; Tichelli A; Gratwohl A
Transfusion; 2008 Apr; 48(4):681-7. PubMed ID: 18208413
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
[TBL] [Abstract][Full Text] [Related]
20. Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective.
Ciaravino V
Semin Hematol; 2001 Oct; 38(4 Suppl 11):12-9. PubMed ID: 11727281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
